Transmedics Group Inc (NASDAQ:TMDX) price on Wednesday, February 05, rose 3.37% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $74.57.
A look at the stock’s price movement, the close in the last trading session was $72.14, moving within a range at $72.81 and $74.79. The beta value (5-Year monthly) was 2.071 while the PE ratio in trailing twelve months stood at 79.89. Turning to its 52-week performance, $177.37 and $55.00 were the 52-week high and 52-week low respectively. Overall, TMDX moved 7.93% over the past month.
Transmedics Group Inc’s market cap currently stands at around $2.50 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 109.49M for the company’s revenue for the quarter, with a low and high estimate of 105M and 111.42M respectively. The average forecast suggests up to a 34.88% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 429.5M, representing a 77.76% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TMDX is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend TMDX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TMDX’s current price about 14.03% and 9.93% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.27, while 7-day volatility ratio is 5.33% and 7.31% in the 30-day chart. Further, Transmedics Group Inc (TMDX) has a beta value of 2.14, and an average true range (ATR) of 4.60. Analysts have given the company’s stock an average 52-week price target of $109, forecast between a low of $90 and high of $125. Looking at the price targets, the low is -20.69% off current price level while to achieve the yearly target high, price needs to move -67.63%. Nonetheless, investors will most likely welcome a -46.17% jump to $109 which is the analysts’ median price.
If we refocus on Transmedics Group Inc (NASDAQ:TMDX), historical trading data shows that trading volumes averaged 1.61 over the past 10 days and 2.05 million over the past 3 months. The company’s latest data on shares outstanding shows there are 33.56 million shares.
The 3.39% of Transmedics Group Inc’s shares are in the hands of company insiders while institutional holders own 107.68% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.99 million on 2025-01-15, giving us a short ratio of 3.54. The data shows that as of 2025-01-15 short interest in Transmedics Group Inc (TMDX) stood at 3258.0003000000006 of shares outstanding, with shares short rising to 8.64 million registered in 2024-12-13. Current price change has pushed the stock 19.60% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TMDX stock continues to rise going into the next quarter.
